Viyash Scientific Acquires BioForLife Italia for €16.98M

Nature of Disclosure: Regulatory intimation under SEBI Listing Regulation 30 regarding execution of definitive acquisition agreement.

Transaction Details:

Alivira Animal Health Limited, Ireland (a step-down wholly owned subsidiary of Viyash Scientific Limited) executed a Sale and Purchase Agreement (SPA) with shareholders of BioForLife Italia S.r.l. on July 21, 2026.
The agreement is for acquisition of 100% of the issued and outstanding share capital of BioForLife Italia S.r.l., Milan, Italy.

Financial Consideration:

Base aggregate consideration remains unchanged at approximately EUR 16.976 million.
Consideration is subject to adjustment for the net financial position in accordance with the SPA.
EUR 15.0 million payable at closing.
Approximately EUR 1.976 million as retained/deferred consideration.

Revised Terms:

The mechanism governing the retained/deferred consideration has been revised as part of final agreed transaction terms.
The deferred consideration is now linked to specified contractual-continuation conditions.
Payment will be made in accordance with the SPA terms.

Conditions Precedent:

Completion of the transaction is subject to receipt of applicable Italian FDI / Golden Power clearance.
Subject to satisfaction or valid waiver of other conditions specified in the SPA.

Previous Disclosure Reference:

Material details of the acquisition were previously disclosed through letter dated June 8, 2026.
Except for the revised deferred-consideration mechanism, all other material details remain unchanged from the June 8 disclosure.

Regulatory Context:

Disclosure made under Regulation 30 of SEBI Listing Regulations.
Purpose is to inform stock exchanges of execution of definitive transaction documentation.

Company Information: